The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients

The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients

Patients with chronic kidney disease (CKD) stage 3–5 are polypharmacy patients. Many of these drugs are metabolized by cytochrome P450 (<i>CYP450</i>) and <i>CYP450.</i> Genetic polymorphism is well known to result in altered drug metabolism capacity. This study determined th...

Full description

Bibliographic Details
Main Authors: Catharina H. M. Kerskes, Carien J. M. E. van den Eijnde, Albert-Jan L. H. J. Aarnoudse, René J. E. Grouls, Birgit A. L. M. Deiman, Maarten J. Deenen
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Pharmacy
Subjects:
pharmacogenetics
chronic kidney disease
medication evaluation
polypharmacy
Online Access:https://www.mdpi.com/2226-4787/11/2/69

Internet

https://www.mdpi.com/2226-4787/11/2/69

Similar Items